GlaxoSmithKline (GSK) said its melanoma treatment Mekinist has been approved by the US Food and Drug Administration.Mekinist has been approved for use in combination with Tafinlar for the treatment of unresectable or metastatic melanoma with BRAF V600E or V600K mutations. The US regulatory gave the combined treatment the green light after a Phase I/II study. Improvement in disease-related symptoms or overall survival has not been demonstrated for Mekinist in combination with Tafinlar."This approval marks another key moment in what continues to be a rapid evolution of the treatment landscape for metastatic melanoma patients," said Paolo Paoletti, President of Oncology, GSK. "Combining agents that target different mechanisms regulating the growth of cancer cells is one of the promising areas in cancer research. We are proud that the first approved combination of targeted therapies in metastatic melanoma is Mekinist and Tafinlar, and our hope is that it will become part of the new standard of care for appropriate patients with BRAF V600E or V600K mutation-positive metastatic melanoma." RD